Proactive Investors - Run By Investors For Investors

Sativa Investments brings in expert to aid its move into the CBD veterinary market

Sativa wants to target the “potentially lucrative” CBD veterinary market, which would see it develop cannabis-based treatments for cats, dogs and horses
vet with cat
The CBD veterinary market has already taken off in North America

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has appointed veterinary expert Dr Nick Horniman as its new director of regulatory affairs.

Horniman has thirty years' experience in the veterinary industry and spent more than twenty of those running a group of private veterinary practices which he has since sold.

His appointment fits in nicely with Sativa’s move into the veterinary market, which it announced last month.

READ: Sativa unveils ambitious new strategic blue-print

As part of his new senior management role, Horniman’s job will be to explore the use of cannabis-based treatments in animals.

He will also be tasked with liaising with the relevant agencies to establish CBD regulation and progress Sativa's medicinal cannabis Growing Licence application.

“As announced in [January], Sativa is planning to enter the potentially lucrative CBD veterinary market through Sativa Veterinary services,” said Sativa chief executive Geremy Thomas.

“The CBD veterinary market has already taken off in North America and Dr Horniman will also advise on how best to go about launching the veterinary arm in the UK.

Horniman has been granted options over 3.1mln shares in the company with an exercise of 6.5p per share.

Sativa shares closed at 5.25p on Friday afternoon.

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
1542204301_heart.jpg
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use